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he consumption of a variety of 
natural and synthetic substances 
can lead to addiction, which 
is commonly deﬁ  ned by the loss of 
control and compulsive consumption 
despite negative consequences. 
Although addictive drugs have diverse 
molecular targets in the brain, they 
share the common initial effect 
of increasing the concentration 
of dopamine released from 
mesocorticolimbic projections. 
In this article, we review recent 
research that has advanced our 
understanding of the molecular 
mechanisms underlying this increase 
of dopamine. Based on this research, 
we propose a new classiﬁ  cation for 
addictive drugs that we believe may 
help in directing research towards 
more effective treatment of addiction 
(see Table 1 and Figure 1). 
Induction of Addiction 
The mesocorticolimbic dopamine 
system originates in the ventral 
tegmental area (VTA), which projects 
most notably to the nucleus accumbens 
(NAc) and the prefrontal cortex 
(PFC). It is a deﬁ  ning commonality of 
all addictive drugs that they increase 
dopamine concentrations in target 
structures of the mesocorticolimbic 
projections [1,2]. The release of 
dopamine from these projections is 
thought to play a crucial role in the 
induction of compulsive addictive 
behaviour. The precise role of 
dopamine in reinforcement and 
the modulation of reward-related 
behaviour remains controversial [3]. 
Most experts in the ﬁ  eld agree that 
some aspects of reward (e.g., euphoria/
pleasure) are dopamine-independent 
[4]. In rats, for example, blockade of 
mesolimbic DA (dopamine) signalling 
with either systemic or intra-NAc 
neuroleptic pre-treatment potentiated 
the sensitivity to nicotine’s rewarding 
properties [5]. Also, dopamine-
deﬁ  cient mice display conditioned 
place preference for morphine [6]. 
Moreover, it is important to realize 
that, once compulsive use has been 
established, addiction is thought to 
be largely dopamine-independent. 
Nonetheless, it is widely accepted that 
the induction of addiction crucially 
involves mesocorticolimbic dopamine. 
Taken together, these ﬁ  ndings 
suggest that it may be possible to 
dissociate the hedonic value of a 
drug from its addictive properties 
using modern molecular tools. 
Such experiments, which may have 
important clinical ramiﬁ  cations, 
obviously depend on further 
mechanistic insight regarding 
drug action. We believe that our 
classiﬁ  cation, based on the molecular 
and cellular mechanisms through 
which addictive drugs increase 
mesocorticolimbic dopamine, will 
provide the conceptual framework 
required to facilitate research to resolve 
these and related issues. 
The Mechanistic Classiﬁ  cation 
of Addictive Drugs
Christian Lüscher*, Mark A. Ungless
Funding: The authors’ salaries are funded by a Royal 
Society University Research Fellowship and the 
University of Geneva. In addition, CL is supported by 
grants from the Swiss National Science Foundation, 
the United States National Institute on Drug Abuse, 
the European Community, and the Leenaards 
Foundation. MU is supported by grants from the 
United Kingdom Medical Research Council, the Royal 
Society, and the Gatsby Charitable Foundation. 
The funders played no role in the submission or 
preparation of this article.
Competing Interests: The authors have declared 
that no competing interests exist. 
Citation: Lüscher C, Ungless MA (2006) The 
mechanistic classiﬁ  cation of addictive drugs. PLoS 
Med 3(11): e437. doi:10.1371/journal.pmed.0030437
Copyright: © 2006 Lüscher and Ungless. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited. 
Abbreviations: CB1R, type 1 cannabinoid receptor; 
DA, dopamine; DAT, dopamine transporter; GABA, 
γ-aminobutyric acid; GHB, γ-hydroxy butyrate; 
GIRK, G protein–coupled inwardly rectifying 
K+; GPCR, G protein  –coupled receptor; MDMA,  
methylenedioxymetamphetamine; MOR, 
µ-opioid receptor; NAc, nucleus accumbens; nAChR, 
nicotinic acetylcholine receptor; NMDA, N-methyl-
D-aspartate; PCP, phencyclidine; PFC, prefrontal 
cortex; SERT, serotonin transporter; THC, delta-9-
tetrahydrocannabinol; VTA, ventral tegmental area
Christian Lüscher is at the Department of Basic 
Neurosciences and Clinic of Neurology, University 
of Geneva, Geneva, Switzerland. Mark A. Ungless is 
at the Medical Research Council Clinical Sciences 
Centre, Imperial College Faculty of Medicine, 
Hammersmith Hospital, London, United Kingdom. 
* To whom correspondence should be addressed. 
E-mail: christian.luscher@medecine.unige.ch
Research in Translation discusses health interventions 
in the context of translation from basic to clinical 
research, or from clinical evidence to practice.
Some of the Key Papers on the 
Cellular Effects of Addictive 
Drugs 
Johnson and North, 1992 [11]: A classic 
paper demonstrating the disinhibitory 
effect of opioids on dopamine neurons.
Cruz et al., 2004 [17]: A current model 
explaining how the popular club drug 
GHB activates VTA neurons via its action 
on the GABAB receptor.
Maskos et al., 2005 [21]: An elegant 
study showing that in knockout 
mice lacking the β2 subunit of the 
acetylcholine receptor, the rewarding 
properties of nicotine can be restored by 
selective re-expression in VTA neurons.
Chen et al., 2006 [39]: A recent paper 
demonstrating that the rewarding 
properties of cocaine are absent in 
mice that express a cocaine-insensitive 
dopamine transporter . 
Ungless et al., 2001 [56]: The ﬁ  rst in 
a series of papers to observe a form 
of long-term synaptic plasticity of 
glutamatergic synapses in the VTA in 
response to addictive drugs. This and 
other adaptive changes common to 
several addictive drugs downstream of 
the dopamine increase are the focus of 
much current research.
Saal et al., 2003 [57]: In this paper the 
authors observe a form of long-term 
synaptic plasticity of glutamatergic 
synapses in the VTA in response to 
several addictive drugs. This and other 
adaptive changes downstream of the 
dopamine increase are the focus of much 
current research.PLoS Medicine  |  www.plosmedicine.org 2006
The Classiﬁ  cation
Addictive drugs are a chemically 
heterogeneous group with very 
distinct molecular targets. Moreover, 
an individual drug may have more 
than one molecular target. Here 
we will focus on those mechanisms 
that are directly responsible for the 
increase in dopamine concentration. 
We distinguish three groups of 
addictive drugs: (1) drugs that bind 
to G protein–coupled receptors 
(GPCRs)—this group includes the 
opioids, cannabinoids, and γ-hydroxy 
butyrate (GHB); (2) drugs that 
interact with ionotropic receptors or 
ion channels—this group includes 
nicotine, alcohol, and benzodiazepines; 
and (3) drugs that target monoamine 
transporters—this group comprises 
cocaine, amphetamine, and 
methylenedioxymetamphetamine 
(MDMA, ecstasy) (see Table 1 and 
Figure 1).
GPCRs that are of the Gi/o family 
inhibit neurons through post-synaptic 
hyperpolarisation and pre-synaptic 
regulation of the transmitter release. 
In the VTA, the action of these drugs 
is preferentially on the γ-aminobutyric 
acid (GABA) neurons that act as local 
inhibitory interneurons. They also 
inhibit glutamate release [7], but in 
the VTA their dominant mechanism 
of action is inhibition of GABA 
neurons leading to a net disinhibition 
of dopamine neurons and increased 
dopamine release. Addictive drugs 
that bind to ionotropic receptors 
and ion channels can have combined 
effects on dopamine neurons and 
GABA neurons, eventually leading 
to enhanced release of dopamine. 
Finally, addictive drugs interfering with 
monoamine transporters block the re-
uptake of dopamine, or stimulate non-
vesicular release of dopamine, causing 
an accumulation of extracellular 
dopamine in target structures. We will 
now discuss examples for each type of 
mechanism in detail.
Class I: Drugs That Activate Gi/o-
Coupled Receptors
Morphine and other opioids. These 
strongly increase the release of 
mesolimbic dopamine by their action 
on µ-opioid receptors (MORs), 
which are expressed on inhibitory 
GABAergic interneurons of the VTA 
[8]. MORs have a dual action: they 
hyperpolarise GABA neurons and 
decrease GABA release. The post-
synaptic hyperpolarisation is mediated 
by Kir3/ G protein–coupled inwardly 
rectifying K+ (GIRK) channels 
coupled to MORs on the soma and the 
dendrites, in analogy to other parts of 
the brain [9], while MORs expressed 
on the pre-synaptic terminals decrease 
release by inhibiting Ca2+ channels or 
activating voltage-gated K+ channels 
[10]. MORs in the two cellular 
compartments therefore rely on 
distinct effectors, which together lead 
to strong inhibition of GABA neurons 
and disinhibition of dopamine neurons 
[11]. 
Delta-9-tetrahydrocannabinol. 
Delta-9-tetrahydrocannabinol (THC) 
binds to type 1 cannabinoid receptors 
(CB1Rs) in the brain. In the VTA, 
these receptors are expressed on 
GABA neurons and on terminals of 
glutamatergic synapses on dopamine 
neurons [12]. Pharmacological 
application of THC causes a net 
disinhibition by decreasing the release 
of the neurotransmitter GABA in 
acute midbrain slices [13]. To date, 
no evidence is available to suggest 
that CB1Rs also activate Kir3/GIRK 
channels in these neurons.
GHB. This is an increasingly 
popular club drug that is readily self-
administered and induces conditioned 
place preference (see Glossary) 
in animal models, and leads to 
addiction in humans [14]. GHB has 
two binding sites in the brain, but its 
pharmacological effects are absent 
in knockout mice lacking functional 
GABAB receptors [15,16], suggesting 
that they are entirely mediated by 
these receptors. Although GABAB 
receptors are expressed on both 
GABA and dopamine neurons of the 
VTA, GHB affects almost exclusively 
GABA neurons at concentrations 
typically obtained with recreational use. 
This happens because the coupling 
efﬁ  ciency of Kir3/GIRK channels in 
dopamine neurons is very low (the 
EC50 differs by an order of magnitude 
Table 1. The Mechanistic Classiﬁ  cation of Drugs of Abuse
Class of Drug Name Main Molecular Target Pharmacology Effect on Dopamine Neurons RR
Class I: Drugs that activate G 
protein–coupled receptors
Opioids MOR (Gi/o) Agonist Disinhibition 4
Cannabinoids CB1R (Gi/o) Agonist Disinhibition 2
GHB GABABR (Gi/o) Weak agonist Disinhibition NA
LSD, mescaline, psilocybin 5-HT2AR (Gq) Partial agonist – 1
Class II: Drugs that bind to 
ionotropic receptors and ion 
channels
Nicotine nAChR (α4β2)  Agonist Excitation, 
disinhibition, 
modulates release
4
Alcohol GABAAR, 5-HT3R, nAChR, 
NMDAR, Kir3 channels
– Excitation 3
Benzodiazepines GABAAR Positive modulator Disinhibition 3
PCP, ketamine NMDAR Antagonist Disinhibitiona 1
Class III: Drugs that bind to 
transporters of biogenic amines
Cocaine DAT, SERT, and NET Inhibitor Blocks DA uptake 5
Amphetamines DAT, NET and SERT, VMAT Reverses transport Blocks DA uptake, synaptic depletion, 
excitation
5
Ecstasy SERT > DAT, NET  Reverses transport Blocks DA uptake, synaptic depletion NA
Drugs fall into one of three categories that target either G protein–coupled receptors, ionotropic receptors/ion channels, or biogenic amine transporters. Note that drugs with RR = 1 [46] 
are readily abused but will not induce addiction.
a Not yet supported by experimental evidence.
5-HTxR, serotonin receptor; GABAxR, γ-aminobutyric acid receptor; Kir3 channels, G protein inwardly rectifying potassium channels; LSD, d-lysergic acid diethylamide; NET, norepinephrine 
transporter; NMDAR: N-methyl-D-aspartate receptor; RR, relative risk of addiction [46]; VMAT, vesicular monoamine transporter 
doi:10.1371/journal.pmed.0030437.t001
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between GABA and dopamine 
neurons), which in turn is due to the 
cell type–speciﬁ  c subunit expression of 
Kir3/GIRK channels [17]. Dopamine 
neurons lack GIRK1, but express GIRK2 
and GIRK3, which when co-assembled 
have a lower afﬁ  nity for the βγ-dimer of 
the Gi/o protein compared to channels 
that contain GIRK1. As a consequence, 
only GABA neurons are hyperpolarised 
at concentrations below 1 mM, causing 
a disinhibition of dopamine neurons.
Class II: Drugs That Mediate Their 
Effects Via Ionotropic Receptors
Nicotine. This drug targets nicotinic 
acetylcholine receptors (nAChRs) 
in the brain. When nicotine binds 
nAChRs they become cation-permeable 
and depolarise the cell. Nicotine 
increases dopamine through a 
complex interplay of actions at these 
ionotropic receptors on GABA and 
dopamine neurons, and glutamatergic 
inputs to dopamine neurons [18]. 
Brief applications of nicotine to these 
neurons in rat brain slices causes a 
depolarisation and increased ﬁ  ring, 
although prolonged exposure leads 
to rapid receptor desensitisation [19]. 
In addition, following desensitisation 
of β2-containing nAChRs on 
GABA neurons, GABA release 
is decreased (i.e., the excitatory 
effect of endogenous acetylcholine 
is reduced), leading to a more 
prolonged disinhibition of dopamine 
neurons [20]. It is evident that β2-
containing nAChRs are responsible 
for the rewarding effects of nicotine 
because β2 knockout mice do not self-
administer nicotine and do not show 
nicotine-evoked dopamine release [21]. 
These deﬁ  cits can be restored through 
in vivo transfection of the β2 subunit in 
the VTA [22]. 
This view is further complicated 
by two more actions of nicotine. 
Homomeric α7-containing nAChRs, 
which are mainly expressed on synaptic 
terminals of excitatory glutamatergic 
afferents onto dopamine neurons in 
the VTA, facilitate glutamate release 
[20]. This effect may also contribute 
to nicotine-evoked dopamine release 
and/or the long-term changes induced 
by the drugs related to addiction (e.g., 
long-term synaptic potentiation of 
excitatory inputs). Furthermore, recent 
evidence suggests that nicotine directly 
modulates dopamine release in the 
NAc [23,24].
Benzodiazepines. Benzodiazepines 
(BZD) increase mesocorticolimbic 
dopamine and can lead to addiction. 
BZD are positive modulators of the 
GABAA receptor. When injected into 
the VTA, the GABAA receptor agonist 
muscimol seems to inhibit interneurons 
more efﬁ  ciently compared to 
dopamine neurons, which may lead to 
a net disinhibition of the dopamine 
neurons [25]. This selectivity may relate 
to cell-type speciﬁ  c subunit expression. 
For example, when dopamine 
neurons were isolated from the VTA 
of transgenic mice that express green 
ﬂ  uorescent protein under the control 
of the tyrosine hydroxylase gene 
promoter, reverse transcriptase–PCR 
analysis revealed the presence of α2, 
α3, and α4 subunits. Conversely, α1 was 
the major subunit expressed in GABA 
neurons [26].
Ethanol. This drug has a complex 
pharmacology. No single receptor 
mediates all of the effects of alcohol 
[27]. On the contrary, alcohol alters 
the function of a number of receptors 
and cellular functions, including 
GABAA receptors [28], Kir3/GIRK 
[29,30] and other K channels 
[31], Ih [32], N-methyl-D-aspartate 
(NMDA) receptors [33], nAChRs 
[34], and 5-HT3 receptors [35]. In 
addition, ethanol also interferes with 
adenosine re-uptake by inhibiting the 
equilibrative nucleoside transporter 
ENT1, although it is not clear if 
this plays a role in ethanol-induced 
dopamine release [36]. How ethanol 
causes the increase in dopamine 
remains unclear. Possibilities include 
a net disinhibition similar to that 
proposed for benzodiazepines or 
direct depolarisation, for example by 
inhibition of a K channel [31].
Class III:  Drugs  That Bind to 
Transporters of Biogenic Amines
Cocaine. In the central nervous 
system, cocaine blocks dopamine, 
noradrenaline, and serotonin uptake 
through inhibition of their respective 
transporters. Blocking of the dopamine 
transporter (DAT) leads to an increase 
of dopamine concentrations in the 
nucleus accumbens. (The ﬁ  ring rate 
of DA neurons of the VTA actually 
decreases with cocaine application, 
which is due to the effects of dopamine 
on D2 autoreceptors on DA neurons 
[37].) In mice lacking DAT, dopamine 
still increases in response to cocaine 
[38], which could be the result of 
inhibition of dopamine uptake by other 
monoamine transporters. Consistent 
with this suggestion, DAT knockout 
mice still self-administer cocaine, and 
this behaviour is abolished in combined 
DAT– serotonin transporter (SERT) 
knockout mice [39]. SERT-mediated 
re-uptake of dopamine only occurs 
in situations where dopamine levels 
are already high, as in DAT knockout 
mice. This is conﬁ  rmed by a study that 
used a knock-in mouse line carrying 
a functional DAT that was insensitive 
to cocaine. In these mice, cocaine did 
not elevate extracellular dopamine 
doi:10.1371/journal.pmed.0030437.g001
Figure 1. The Dominant Targets Involved in Increasing Dopamine for the Major Types of 
Addictive Drugs
G, Gi/o-coupled receptors; i, ionotropic receptors/ion channels; T, monoamine transporters
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in the nucleus accumbens, and did 
not produce reward, as measured by 
conditioned place preference [40]. 
Finally, it is important to point out that 
selective SERT inhibition in humans 
(e.g., ﬂ  uoxetine to treat depression) 
does not carry any addiction liability. 
Amphetamine, methamphetamine, 
and their many derivates. These exert 
their effects by reversing the action 
of biogenic amine transporters at the 
plasma membrane [41]. Amphetamines 
are substrates of these transporters 
and are taken up into the cell. Every 
molecule that is taken up generates 
a current causing a depolarisation of 
the dopamine neurons, which could 
contribute to enhanced dopamine 
release [42]. In addition, once in the 
cell, amphetamines interfere with the 
vesicular monoamine transporter, 
depleting synaptic vesicles. As a 
consequence, dopamine increases in 
the cytoplasm from where it is released 
by plasma membrane transporters 
working in reverse. In other words, 
normal vesicular release of dopamine 
decreases (i.e., synaptic vesicles contains 
less transmitter, the quantal content 
becomes smaller), while non-vesicular 
release increases. Similar mechanisms 
apply for other biogenic amines such as 
serotonin and norepinephrine.
Methylenedioxymetamphetamine 
(ecstasy). As for the amphetamines, 
MDMA causes the release of biogenic 
amines by reversing the action of their 
respective transporters. Although 
MDMA has a preferential afﬁ  nity 
for SERTs and therefore increases 
the extracellular concentration of 
serotonin, it also strongly increases 
dopamine [43]. 
Drugs of Abuse Yet to Be Classiﬁ  ed
There are a number of abused drugs 
about which there is no clear consensus 
concerning their addictive properties 
(e.g., hallucinogens and dissociative 
anaesthetics). For example, LSD, which 
is widely abused, does not appear to 
be addictive. Animals will not self-
administer hallucinogens, suggesting 
that they are not rewarding [44]. 
Importantly, these drugs fail to evoke 
dopamine release, further supporting 
the idea that only drugs that activate 
the mesolimbic dopamine system are 
addictive. Instead, the critical action 
of hallucinogens may be increased 
glutamate release in the cortex, 
presumably through a pre-synaptic 
effect on 5-HT2A receptors expressed on 
excitatory afferents from the thalamus 
[45]. 
The main effect of the NMDA 
receptor antagonists phencyclidine 
(PCP) and ketamine are feelings 
of separation of mind and body 
and, at higher doses, stupor and 
coma, which is why they are called 
dissociative anaesthetics. Based on 
early assessments, NMDA receptor 
antagonists have been classiﬁ  ed as 
non-addictive drugs of abuse [46]. 
This classiﬁ  cation has recently been 
questioned for PCP. For example, 
PCP has some reinforcing properties 
in rodents when applied directly to 
the NAc and the PFC [47]. Moreover, 
increased dopamine levels were 
measured in vivo with micro-dialysis 
after systemic or PFC injection of PCP 
in freely moving rats. Similar results 
were also obtained with local injections 
of MK-801, a more selective and potent 
NMDA receptor antagonist than PCP, 
which supports the conclusion that 
PCP’s effect on dopamine is mediated 
via the inhibition of NMDA receptors 
[48]. In this case, PCP would be a Class 
II drug according to our classiﬁ  cation.
Inhalant abuse is deﬁ  ned by the 
recreational exposure to chemical 
vapours, such as nitrates, ketones, and 
aliphatic and aromatic hydrocarbons. 
In some countries it is particularly 
common among children, and some 
chemicals do induce addiction [49]. 
The mechanism of action remains 
unknown for most volatile substances. 
A very limited literature provides 
evidence that some inhalants alter 
the function of ionotropic receptors 
and ion channels throughout the 
central nervous system [50]. Nitrous 
oxide, for example, binds to NMDA 
receptors [51,52] and fuel additives 
enhance the GABAA receptor function 
[53]. Toluene increases ﬁ  ring in VTA 
neurons [54] and causes conditioned 
place preference [55]. Others, such 
as amyl nitrite (“poppers”), primarily 
produce smooth muscle dilatation, 
and enhance erection, but are not 
addictive. While this literature suggests 
that some inhalants may be Class II 
addictive drugs, clearly more research 
will be needed to conﬁ  rm this choice.
Implications for Research
We have presented a new mechanistic 
classiﬁ  cation system for addictive drugs. 
There are a number of key features of 
this system. First, there are three types 
of mechanism. Second, each addictive 
drug only activates the dopamine 
system through a single mechanism 
(with the possible exception of 
ethanol, which has multiple molecular 
targets whose relative contributions 
to addiction remain elusive). Third, 
within each type of mechanism the 
effect on the dopamine system is 
similar (e.g., Class I drugs all activate 
dopamine neurons via disinhibition). 
Although substantial progress 
into unravelling the neurobiological 
bases of addiction has been made, 
many open questions remain and 
few effective treatments are currently 
Glossary 
Conditioned place preference: 
A behavioural test for examining the 
rewarding properties of drugs. The 
preference of a particular environment 
associated with drug exposure is 
measured by comparing the time an 
animal spends in the compartment 
where the drug was previously 
administered compared to a control 
compartment.
Coupling efﬁ  ciency: The efﬁ  ciency 
with which a given G protein–coupled 
receptor can activate an effector.
DARP32: Dopamine and cAMP-regulated 
phosphoprotein. A key target protein for 
increased dopamine that plays a role in 
signalling the effects of many addictive 
drugs.
DeltaFosB: A transcription factor that 
is induced in areas such as the NAc in 
response to many addictive drugs, and 
thought to be involved in the long-term 
maintenance of addictive behaviour.
EC50: 50% effective concentration, i.e., 
the concentration of an agonist that 
produces 50% of the maximal effect.
Equilibrative nucleoside transporter 
ENT1: Transporter responsible for the re-
uptake of adenosine.
Homomeric α7-containing nAChRs: 
Nicotinic acetylcholine receptors formed 
by ﬁ  ve subunits of the α7 type.
Kir3/GIRK channels: One class of 
inwardly rectifying potassium channels; 
Kir3 are also termed G protein–coupled 
inwardly rectifying K+ channels. 
Quantal content: The amount of 
neurotransmitter released by a single 
vesicle.
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available. Much current research is 
therefore aimed at understanding 
the neuroadaptive changes induced 
by addictive drugs, such as increased 
expression of deltaFosB and DARP32 
[1] or the effects on excitatory 
glutamate transmission [56–58]. The 
present classiﬁ  cation represents a 
framework that will facilitate research 
aiming at understanding how each 
drug induces the adaptive changes 
listed above and predicts that drugs 
of the same group are likely to share 
similar mechanisms.
Implications for Developing Better 
Treatments for Addiction
Understanding the early phases of the 
induction of adaptive processes will also 
be important for the discovery of novel 
pharmacological treatment strategies. 
If activation of the dopamine system is 
indeed crucial for the development of 
addiction, then an interesting strategy 
may be to inhibit the mesocorticolimbic 
DA system (either pharmacologically or 
through direct stimulation). This idea 
is further supported by the observation 
that increases in dopamine play an 
important role in relapse, particularly 
drug-induced relapse [59,60]. In this 
context, the present classiﬁ  cation 
would also serve to identify and 
organise treatments at the level of 
the VTA. For example, naloxone will 
block the effect of opioids, while the 
high afﬁ  nity GABAB receptor agonist 
baclofen would inhibit GABA and 
dopamine neurons, thus efﬁ  ciently 
blocking DA release.
Treatments in use, or at pre-clinical 
stages of development, are either drug-
speciﬁ  c (e.g., vaccines or antagonists 
that directly block drug action, or 
agonists for use as drug substitutes) or 
target a mechanism that is common to 
several drugs (e.g., medications that 
reduce craving in multiple forms of 
addiction) [57]. Many new addiction 
treatments (for a comprehensive 
list of approved and experimental 
medications see [61]) appear to 
operate downstream of initial targets 
(e.g., naltrexone or acamprosate 
for opiate and alcohol addiction), 
although their precise mechanisms 
of action are not entirely clear. 
Our classiﬁ  cation points to a third 
approach of developing treatments 
for different classes of drugs based 
on the mechanisms through which 
they increase dopamine. For example, 
targeting the DAT should be useful 
in treating addiction to any Class 
III drug. The same may be true for 
future treatments that interfere with 
G protein–coupled signalling—such 
treatments may be useful for all Class I 
drugs. 
Finally, we hope that our strikingly 
simple mechanistic classiﬁ  cation will 
provide students and clinicians with 
a useful conceptual framework for 
understanding a diverse and often 
complex literature concerning such an 
important medical issue.  
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